Jefferies Lifts Numbers on Biogen (BIIB) Post Q1

April 26, 2013 8:03 AM

Jefferies raised estimates and its price target on Buy-rated Biogen (NASDAQ: BIIB) from $215 to $248 following Q1 results.

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found